It’s the latest step from pharmacy benefit managers to respond to relentless criticism from politicians and regulators over ...

Cigna (NYSE:CI) Group, and UnitedHealth Group Inc (NYSE:UNH) were down around 1% after the Federal Trade Commission (FTC) accused their pharmacy benefit manager units of imposing ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ($CVS) and Cigna ...

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

Cigna’s Express Scripts called the report ... what our health plans spend on medications in a year” and said the FTC had failed to address the underlying causes of rising drug prices.

The FTC released a 60-page report Tuesday targeting the biggest three pharmacy benefit managers, claiming the companies hiked ...

TD Cowen analyst Ryan Langston maintained a Buy rating on Cigna (CI – Research Report) today and set a price target of $391.00. The company’s ...

FTC said the "Big 3 PBMs" — CVS’s Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx — imposed markups of hundreds to thousands of percent on critical drugs, including those ...